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http://www.retrovirology.com/content/10/1/152RESEARCH Open AccessCD8+ T cells from HLA-B*57 elite suppressors
effectively suppress replication of HIV-1
escape mutants
Christopher W Pohlmeyer1, Robert W Buckheit III1,3, Robert F Siliciano1,2 and Joel N Blankson1*Abstract
Background: Elite Controllers or Suppressors (ES) are HIV-1 positive individuals who maintain plasma viral loads
below the limit of detection of standard clinical assays without antiretroviral therapy. Multiple lines of evidence
suggest that the control of viral replication in these patients is due to a strong and specific cytotoxic T lymphocyte
(CTL) response. The ability of CD8+ T cells to control HIV-1 replication is believed to be impaired by the development
of escape mutations. Surprisingly, viruses amplified from the plasma of ES have been shown to contain multiple escape
mutations, and it is not clear how immunologic control is maintained in the face of virologic escape.
Results: We investigated the effect of escape mutations within HLA*B-57-restricted Gag epitopes on the CD8+ T cell
mediated suppression of HIV-1 replication. Using site directed mutagenesis, we constructed six NL4-3 based viruses
with canonical escape mutations in one to three HLA*B-57-restricted Gag epitopes. Interestingly, similar levels of
CTL-mediated suppression of replication in autologous primary CD4+ T cells were observed for all of the escape
mutants. Intracellular cytokine staining was performed in order to determine the mechanisms involved in the
suppression of the escape variants. While low baseline CD8+ T cells responses to wild type and escape variant
peptides were seen, stimulation of PBMC with either wild type or escape variant peptides resulted in increased
IFN-γ and perforin expression.
Conclusions: These data presented demonstrate that CD8+ T cells from ES are capable of suppressing replication of
virus harboring escape mutations in HLA-B*57-restricted Gag epitopes. Additionally, our data suggest that ES CD8+ T
cells are capable of generating effective de novo responses to escape mutants.
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In primary HIV-1 infection, vigorous viral replication results
in plasma virus levels as high as one million copies/mL
of HIV-1 RNA. As cellular immune responses develop,
plasma virus levels decrease, and a viral set point is
established. A subset of HIV-1-infected individuals known
as Elite Controllers or Suppressors (ES), maintain a viral
set point below the limit of detection of standard clinical
assays (<50 copies of HIV-1 RNA/mL of blood [1-4]). Early
studies suggested that some long-term non-progressors
(LTNPs) and ES are infected with defective viruses [5,6]. In
contrast, more recent studies have determined that many* Correspondence: jblanks@jhmi.edu
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article, unless otherwise stated.ES are infected with viruses that are fully replication
competent, suggesting that host factors rather than infec-
tion by defective virus are responsible for ES status [7-11].
Some HLA alleles affect disease progression, including
HLA-B*27, HLA-B*51, HLA-B*57/58, and HLA-B*35
[12,13]. Multiple cohort studies have demonstrated that
the HLA-B*57 allele is overrepresented in ES [14-20].
This finding has been confirmed by multiple GWAS
studies [21-26]. However, the majority of HIV-1-infected
HLA-B*57+ patients develop progressive disease, and are
thus termed chronic progressors (CPs) [14]. The protection
conferred by HLA-B*57 and HLA-B*27 is thought to
be mediated by effective CD8+ T cell responses against
conserved immunodomniant epitopes that are presented
by MHC class I proteins [18,27-32]. Comparison studies
of HLA-B*57+ ES and CPs have provided some detailstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public












































Figure 1 Fitness cost of canonical HLA-B*57 escape mutations.
A. Average infection by seven NL4-3 escape variants in uninfected
individuals. Viral inoculum was quantified by relative qPCR. 105 CD4+
T cells were infected in a 96-well plate in triplicate. Infection was
determined by GFP expression by flow cytometry. Wild type NL4-3
(black) showed the highest level of infection, while NL4-3 escape
mutant variants showed reduced maximal infection (I147L, orange;
A146P, navy; A163S, red; A146P/A163S, purple; T242N/G248A, brown;
A146P/A163S/T242N/G248A, teal). Error bars represent SEM. n = 4.
B. Maximal infection of each escape variant is compared relative to
wild type NL4-3 virus.
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bulk peripheral blood mononuclear cells (PBMCs) with
Gag peptides induces greater proliferation as well as
more robust granzymes A/B and perforin expression in
CD8+ T cells from HLA-B*57+ ES compared to HLA-B*57+
CPs [18].
Some nonsynonymous mutations in epitopes enable the
virus to escape from the cytotoxic T lymphocyte (CTL)
responses. The role these escape mutations play in de-
termining protection versus progression in HLA-B*57
positive patients is controversial. A correlation between
the number of HLA-B*57 Gag epitopes and the level of
viremia was observed in a cohort of HLA-B*5703 positive
patients with Clade C HIV-1 infection [33]. In another
study, the development of escape mutations was temporally
associated with virologic breakthrough in a patient who
had maintained undetectable viral loads for a year after
infection [34]. In contrast, studies of early infection in
other HLA-B*57/5801 positive patients have not found a
correlation between the accumulation of escape mutations
and virologic breakthrough [35,36]. Furthermore, one study
found no difference in the frequency of escape mutations
in HLA-B*57-restricted epitopes in proviral clones ampli-
fied from ES when compared to CPs [37]; other studies
found that while escape mutations were largely absent from
provirus amplified from CD4+ T cells of ES, virus amplified
from the plasma of the same subjects contained a high
frequency of escape mutations [38,39]. In this study, we
sought to explain how ES maintain undetectable levels
of plasma virus despite the presence of circulating HIV-1
isolates that contain numerous escape mutations. Specific-
ally, we asked whether CD8+ T cells from these patients
were capable of inhibiting the viral replication of engi-
neered escape mutants. We demonstrate that ES can
inhibit the replication of escape variant HIV-1 and suggest
that these patients are capable of generating protective
de novo responses against the escape mutant variants.
This work has implications for the design of therapeutic T
cell vaccines to prevent the progression of HIV-1 disease.
Results
Effect of escape mutations in HLA-B*57-restricted Gag
epitopes on viral fitness
The effect of several escape mutations on viral fitness has
been explored in vivo and in vitro [40-45]. We focused on
escape mutations in the three HLA-B*5703 restricted Gag
epitopes: IW9 (Gag 147–155), KF11 (Gag 162–172), and
TW10 (Gag 240–249). We have previously demonstrated
that HLA-B*5703 positive ES in our cohort do not target
the fourth HLA-B*57-restricted Gag epitope QW9 (Gag
308–316) [38] and therefore we did not include this
epitope in our analysis. To address the fitness cost of these
escape mutations, we introduced a series of mutations into
the reference isolate NL4-3 and generated GFP-expressingHIV-1 pseudoviruses carrying these mutations. Virus
concentrations were measured in triplicates by RT-PCR.
We then infected PHA-activated CD4+ T cells from four
seronegative healthy donors using a 2 log range of virus
inoculums. Infection curves for the seven viruses are
shown in Figure 1A.
Infectivity relative to the reference clone NL4-3 was
taken as a measure of fitness. Infectivity curves plateaued
at different points for different mutants. A best fitting
curve was generated with GraphPad to calculate a non-
linear least squares regression model and was used to
determine the theoretical maximal infection. Additional
file 1: Figure S1 shows the best fit curve for each of the
assayed viruses. This theoretical maximal infection was
used to determine the relative percentage of maximal
infection relative to the reference clone NL4-3 (Figure 1B).
The I147L and A146P mutations, which are found in the
IW9 epitope of p24, each had a minimal effect on viral
fitness with calculated fitness levels of 88 percent and 90
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A163S mutation (72 percent relative fitness) had a larger
effect on fitness consistent with a prior study that showed
that mutations in this epitope in Clade C virus had a
major impact on replication capacity [33]. When the
A163S mutation was combined with the A146P mutation,
a further decrease in fitness was observed (50 percent rela-
tive fitness). The T242N/G248A variant had an intermedi-
ate level of fitness (67 percent relative fitness). Interestingly,
the A146P/A163S/T242N/G248A variant (49 percent
relative fitness) showed no additional loss of fitness than
what was observed with the A146P/A163S variant.
ES CD8+ T cells suppress replication of viruses containing
CTL escape mutations
We next determined whether CD8+ T cells from ES could
inhibit the infection of viruses harboring escape mutations.
We isolated CD4+ and CD8+ T cells from seven HLA-
B*5703+ ES and five healthy seronegative donors. The ES
did not have any other protective alleles. Unstimulated
CD4+ T cells were infected with each variant individually
and were co-cultured with unstimulated CD8+ T cells at
various effector to target ratios for three or five days.
Interestingly, unstimulated CD8+ T cells from ES were
capable of suppressing each variant (Figure 2A), whereas
healthy donors had no suppressive capabilities (Figure 2D).
The percentage of suppression decreased at lower effector
to target ratios. Compared to day three, day five showed
increased levels of suppression at all effector to target
ratios (Figure 2A).
A prior study demonstrated that CD8+ T cells that were
stimulated with peptides were more effective at eliminating
HIV-1 infected target cells [18]. We therefore stimulated
PBMCs from the same group of ES and healthy donors
with a combination of three wild type peptides (wild type
IW9, wild type KF11, and wild type TW10) or a combin-
ation of three escape variant peptides (mutant IW9
(I147L), mutant KF11 (A163S), or mutant TW10 (T242N/
G248A)) in the presence of 10 units/mL IL-2. After seven
days of stimulation, CD8+ T cells from both stimulation
groups were individually isolated and cultured with
unstimulated CD4+ T cells that were infected with either
wild type virus or one of the 6 escape mutants. Interest-
ingly, there was no statistical difference in the suppressive
capacity of CD8+ T cells that were stimulated with either
wild type or escape variant peptides (Figure 2B, C and
Additional file 2: Figure S2). Figure 3 shows the suppressive
ability of unstimulated CD8+ T cells from each patient at
day three and day five. Statistically significant differences in
levels of suppression between wild type and escape variants
were seen only for A163P at a one to two effector to target
ratio (Figure 3A); this difference was not seen at any other
effector to target ratios. Taken together, these results
demonstrate that ES are capable of recognizing escapevariant epitopes as effectively as their non-mutated
counterparts.
Stimulation of CD8+ T cells with wild type or escape
variant peptides increases expression of interferon
gamma and perforin
To determine the mechanism of CTL suppression of
escape mutants, we analyzed the expression of IFN-γ
and perforin in freshly isolated CD8+ T cells and CD8+
T cells that were primed with either wild type or escape
variant peptides. Freshly isolated PBMCs and PBMCs
from each stimulation group were stimulated overnight
with individual wild type or escape variant peptides.
Freshly isolated CD8+ T cells were observed to have very
low levels of IFN-γ expression in response to each peptide
(Figure 4A, B, C left panel). In contrast, culture of PBMCs
with wild type peptides over a 7 day period prior to
overnight stimulation with wild type peptides resulted
in a statistically significant increase (P < 0.05) in IFN-γ
expression (Figure 4A, B, C center panel). A similar re-
sponse was seen when the CD8+ T cells were stimulated
with the analogous escape variant peptide. Interestingly,
IFN-γ expression in response to restimulation with wild
type or escape variant peptides individually were similar in
CD8+ T cells that were cultured for 7 days in the presence
of either wild type or escape variant peptides (Figure 4A,
B, C right panel).
Because perforin expression is associated with CTL-
mediated killing [18,31,46], we also examined perforin
expression by stimulated CD8+ T cells. Low levels of
perforin and IFN-γ double positive cells were observed
when freshly isolated CD8+ T cells were stimulated with
wild type or escape variant peptides (Figure 4D, E, F left
panel). In contrast, CD8+ T cells that had been cultured
for 7 days in the presence of wild type or escape variant
peptide cocktails were observed to have an increase in the
percentage of IFN-γ and perforin double positive CD8+ T
cells when stimulated overnight with either wild type or
escape variant peptides. Interestingly, culturing PBMCs in
the presence of wild type peptides or escape variant
peptide cocktails resulted in similar levels of CD8+ T cells
that co-expressed IFN-γ and perforin in response to
overnight peptide stimulation. Additionally, overnight
stimulation with KK10 (Gag 263–272), an immunodo-
minant HLA-B*27 specific peptide, resulted in no increase
in IFN-γ or perforin expression, confirming the specificity
of the enhanced CD8+ T cell responses to the HLA-B*57-
restricted peptides.
To determine whether similar responses were present
in HLA-B*57 positive CPs, we also analyzed CD8+ T cells
from five CPs on suppressive HAART regimens, two CPs
who recently had detectable viremia, and one CP with high
levels of viremia who was not on HAART. With freshly
isolated PBMCs, there was very low IFN-γ expression on
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Elite Suppressors Healthy Donors
Figure 2 Suppression of replication of NL4-3 escape variant viruses. A-C: Unstimulated CD4+ T cells from HLA-B*5703 positive ES were
infected with one of seven NL4-3 variants (wild type, black; I147L, orange; A146P, navy; A163S, red; A146P/A163S, purple; T242N/G248A, brown;
A146P/A163S/T242N/G248A, teal) and cultured with autologous CD8+ T cells isolated from fresh PBMCs (A) or PBMCs stimulated with either wild
type (B) or escape variant (C) HLA-B*57- Gag restricted Gag peptides for 7 days before isolation. CD8+ T cells were co-cultured with infected CD4+ T
cells at three effector to target ratios. D-F: Unstimulated CD4+ T cells from healthy donors were infected with one of the seven NL4-3 variants used
above and co-cultured with CD8+ T cells as was done with ES (D, unstimulated; E, wild type peptide stimulated; F, escape variant stimulated). Infection
of CD4+ T cells was quantified by flow cytometry on days 3 (left) and 5 (right) after infection by GFP expression. Median values are plotted. For ES,
n = 7. For healthy donors, n = 5.
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peptides (Figure 5A, B, C left panel). Stimulation of cells
with wild type peptides or escape variant peptides induced
an increase in IFN-γ expression by CD8+ T cells in some
patients after overnight stimulation with TW10 or KF11
(Figure 5A, B, C center and right panels). The percentage
of CD8+ T cells that co-expressed IFN-γ and perforin in-
creased from the unprimed baseline (Figure 5E, F, G),
though generally not as dramatically as the increase seen
in ES. This is consistent with the enhanced proliferative
capacity of ES HIV-specific CD8+ T cells [18,27]. Interest-
ingly, the patients on HAART who recently had detectable
levels of viremia had higher responses than the patientson suppressive HART regimens who maintained un-
detectable viral loads consistent with a boosting effect
of viral replication.
Discussion
CTL responses against Gag epitopes have been associated
with virologic control [47-49] and Gag-specific CD8+ T
cells can target incoming virions and therefore have the
potential to kill cells prior to productive infection [50-54].
The CTL response has been associated with the appearance
of escape mutations in HIV and SIV infection. The
mechanism of escape observed for individual mutations



































































































Figure 3 Individual suppression of NL4-3 escape variant viruses. Unstimulated CD4+ T cells from HLA-B*5703+ ES were infected with one of
seven NL4-3 variants (wild type, black; I147L, orange; A146P, navy; A163S, red; A146P/A163S, purple; T242N/G248A, brown; A146P/A163S/T242N/
G248A, teal) and cultured with autologous unstimulated CD8+ cells at three effector to target ratios. A shows maximal suppression on day 3; B
shows maximal suppression on day 5. Black horizontal bars indicate median. Asterisk indicates P < 0.05.
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recognition of the MHC:peptide complex. Mudd et al.
observed that Mamu-B*00801 macaques that controlled
viral infection acquired few, if any, escape mutations in
Vif and Nef epitopes, whereas macaques that progressed
acquired several during the acute phase, suggesting that
control may result from a immunologic pressure that
prevents the appearance of escape mutations [55]. In
contrast, Migueles et al. found that there was no differencebetween HLA-B*57+ CPs and HLA-B*57+ ES in the fre-
quency of escape mutations in Gag [37], and Bailey et al.
found a high frequency of escape mutations in HLA-B*57-
restricted epitopes present in virus amplified from ES
plasma [38,39].
In this study, we sought to determine how ES maintain
control of viral replication despite circulating escape
mutant viruses in the plasma. We constructed a series of

























































































































































































































































































WT/Mutant Peptide (2 µg/mL) WT/Mutant Peptide (2 µg/mL)
Figure 4 Intracellular cytokine staining of ES CD8+ T cells. A-D: CD8+ T cells of HLA-B*57 positive ES were either freshly isolated (left) or stimulated
with either wild type (center) or escape variant (right) HLA-B*57-restricted Gag peptides for 7 days. Cells from each group underwent an overnight
stimulation with individual peptides. Percentage of CD8+ T cells expressing IFN-γ when stimulated overnight with TW10 (A), KF11 (B), and IW9 (C) in
blue, or the escape mutant variant peptide containing T242N/G248A (A), A163S (B), and I147L (C) mutations in red is shown. E-H: Percentage of CD8+
T cells expressing both IFN-γ and perforin after restimulation with TW10 (E), KF11 (F), and IW9 (B) in blue, or the escape mutant variant peptide
containing T242N/G248A (E), A163S (F), and I147L (G) in red is shown. D and H show CD8+ T cells that express IFN-γ or co-express IFN-γ and perforin
when PBMCs were stimulated overnight with Gag 263-272 (KK10, HLA-B*27+ peptide). Black horizontal bars indicate statistically significant difference
(P < 0.05) between samples when stimulated overnight with the same variant peptide; gray horizontal bars indicate statistically significant difference
(P < 0.05) between samples when stimulated overnight with opposite variant peptide.
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limited by the fact that we did not study viral inhibition of
autologous escape mutants isolated from each ES, the
A146P and T242N/G248A mutations in the IW9 and
TW10 epitopes are commonly seen in our cohort [38].
Mutations in KF11 are rare in Clade B HIV-1 isolates,
but one patient was found to have the A163S mutation
and we demonstrated that this was in fact an escape
mutation in a prior study [38]. In agreement with other
studies [40-44], we found that some of the escape mutants
we generated were detrimental to viral fitness. While
attenuating escape mutations may contribute to elite
control [56], viruses from CPs have been observed to havesimilar escape mutations, although compensatory muta-
tions may partially restore viral fitness [57,58].
Klenerman and Zinkernagel demonstrated a limitation
to the adaptive immune response: original antigenic sin
[59]. In brief, when CTLs respond to an intracellular
pathogen, any variant of the original pathogen elicits the
activation of the original memory response, which is
potentially less effective in the face of the new variant of
the pathogen [60]. Allen et al. demonstrated in a cohort
of HLA-A*11+ individuals that the CTL response that
recognizes escape variants was incapable of recognizing
the original, un-mutated variants, as these CD8+ T cells



























































































































































Figure 5 Intracellular cytokine staining of CP CD8+ T cells. A-D: CD8+ T cells of HLA-B*57 positive CP were either freshly isolated (left) or
stimulated with either wild type (center) or escape variant (right) HLA-B*57-restricted Gag peptides for 7 days. CPs were either on suppressive
HAART regiments with undetectable viral loads (circles), were on HAART regimens but recently had detectable levels of viremia (triangles), or were
not on HAART and had high levels of viremia (diamond). Cells from each group underwent an overnight stimulation with individual peptides.
Percentage of CD8+ T cells expressing IFN-γ when restimulated with TW10 (A), KF11 (B), and IW9 (C) in blue, or the escape mutant variant
peptide containing T242N/G248A (A), A163S (B), and I147L (C) mutations in red is shown. E-H: Percentage of CD8+ T cells expressing both IFN-γ
and perforin after overnight stimulation with TW10 (E), KF11 (F), and IW9 (G) in blue, or the escape mutant variant peptide containing T242N/
G248A (E), A163S (F), and I147L (G) mutations in red is shown. D and H show CD8+ T cells that express IFN-γ or co-express IFN-γ and perforin
when PBMCs were stimulated overnight with Gag 263-272 (KK10, HLA-B*27+ peptide). Black asterisks indicate statistically significant difference
(P < 0.05) between samples when restimulated with the same variant peptide; gray asterisks indicates statistically significant difference (P < 0.05)
between samples when restimulated with opposite variant peptide.
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but during chronic infection in HLA-A*02+ patients [62].
Lichterfeld et al. have shown that HLA-B*27+ individuals
can develop a de novo response to the immunodominant
KK10 L268M escape mutation during chronic infection
[63]. In a previous study, HLA-B*57/58+ children infected
perinatally showed a remarkable ability to generate de
novo CD8+ T cell responses to escape mutations in theTW10 Gag epitope. Interestingly, there was little recogni-
tion of the wild type TW10 epitope in these children
[64]. Another study found that CD8+ T cells from both
HLA-B*57+ ES and HLA-B*57+ viremic patients made
responses to autologous TW10 escape variant peptides
[65]. Furthermore, we previously have described CD8+ T
cell de novo responses to escape mutants in HLA-B*57+
ES [38,66].
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secretion of this cytokine is not a correlate of immunity in
HIV infection [67,68]. Furthermore, discrepancies between
IFN-γ ELISPOT assays and CD8+ T cell-mediated killing of
both SIV and HIV escape variants have been reported
[69,70]. Therefore in order to determine whether protective
de novo responses were present in ES, we looked at the
ability of CD8+ Tcells to suppress replication of escape mu-
tants. We used the suppression assay because Saez-Cirion
and colleagues have demonstrated that the ability of
unstimulated primary CD8+ T cells to inhibit viral rep-
lication correlates with elite control of HIV-1 infection
[71,73], and we have recently confirmed this finding
[72]. In a prior study, we demonstrated that CD8+ T
cells from an HLA-B*57 ES suppressed multiple rare
autologous TW10 escape variants by a non-cross reactive
de novo response [74]. In the current study, we demon-
strated that this phenomenon is not limited to that one ES
or to rare TW10 epitopes. CD8+ T cells from multiple
HLA-B*5703+ ES were able to suppress the replication
of virus containing common escape mutations in all three
HLA-B*5703-restricted Gag epitopes. This is probably due
to the development of CD8+ T cells that produce perforin
in response to wild type and escape variant peptides.
Interestingly, while the presence of residual intracellular
concentrations of antiretroviral drugs prevented us from
infecting CD4+ T cells and performing the suppression
assay with cells from HLA-B*57+ CPs, we demonstrated
de novo IFN-γ production when CD8+ T cells of some CPs
were stimulated with variant peptides. This is consistent
with an earlier study which showed that HLA-B*57+ CPs
made IFN-γ responses to autologous TW10 variants that
were as strong, if not stronger, than the responses made by
HLA-B*57+ ES [65]. Thus the elite control of viral replica-
tion is not solely due to the ability to recognize escape
mutants. Rather, our work suggests that ES maintain
control of viremia in spite of virologic escape in immuno-
dominant epitopes because they develop protective CD8+
T cell responses to the escape variants. In contrast, CPs
generally do not develop protective CTL responses
[18,27,31,46,71-73], and a study that compared HLA-
B*57+ ES to HLA-B*57+ CPs found that proliferative
CTL responses as well as perforin secretion in response to
HIV antigens correlated strongly with elite suppression
[27]. Interestingly, we show here that stimulation with
wild type and escape variant peptides can induce perforin
responses to both peptides in some CPs. Thus, it may be
possible to immunize subjects with both wild type and
escape variant peptides in order to induce protective
CD8+ T cell responses that will prevent the emergence
of common escape mutations. Taken together, it appears
that ES CD8+ T cells may develop effective CTL sup-
pressive responses to escape variants; these responses in
addition to the reduced fitness of the escape variants,may explain how ES maintain levels of viremia in the
face of virologic escape.
Conclusion
In this study, we demonstrate the ability of CD8+ T cells
from ES to suppress replication of viruses harboring escape
mutations in HLA-B*57-restricted Gag epitopes. The re-
duced fitness of these escape mutants may also contribute
to elite control. Additionally, protective de novo CD8+ T
cell responses to both wild type and escape variant
peptides could be generated in ES and some CPs by
priming PBMCs with either peptide. Induction of CD8+ T
cells that could respond to wild type virus as well as




The HLA-B*57+ patients used in the study are described
in Table 1.
Consent
All studies were approved by the Johns Hopkins Institu-
tional Review Board. All patients and HIV negative donors
provided written informed consent before participation in
this study.
Construction of escape mutant viruses
Single-round infection by pseudotyped NL4-3 virus has
been previously described [75]. In brief, eGFP was intro-
duced in the env reading frame of pNL4-3, thus creating
an env deficient pNL4-3 that allows for analysis of infected
cells by flow cytometry. Individual point mutations were
introduced by site directed mutagenesis (Agilent Tech-
nologies QuikChange II kit) and primers: A146P 5′ ggcaa
atggtacatcagcccatatcacctagaactttaaatgc, I147L 5′ ggtacatca
ggccctatcacctagaactttaaatgcatgg, A164S 5′ ggtaaaagtagtaga
agagaagtctttcagcccagaagtaatacc, and T242N/G248 5′ ccctt
caggaacaaatagcgtggatgacacataatccacc followed by 5′ ggaac
tactagtaaccttcaggaacaaatagcgtgg. A146P/A163S was made
by sequential mutagenesis. A146P/A163S/T242N/G248A
was made by insertion of the digestion product of T242N/
G248A with SpeI and SbfI into the A146P/A163S plasmid.
These plasmids were sequence confirmed and individually
cotransfected with pCI containing the III-B env reading
frame into HEK293T cells using Lipofectamine 2000.
48 hours after transfection, supernatant was collected
and virus was isolated by ultracentrifugation at 50,000 × g
through a 20% sucrose cushion for 2 h.
PBMC peptide stimulation
PBMCs were isolated from blood of ES, CP, and healthy
donors by Ficoll gradient centrifugation. PBMCs were
then cultured in RPMI 1640 supplemented with 10% FBS


















ES5 62/F 1990 617 <20 NA NA NA - NA
ES6 57/F 1992 675 < 20 NA NA NA - NA
ES8 61/M 2003 643 < 75 NA NA NA - NA
ES22 52/M 2009 1638 < 20 NA NA NA - NA
ES23 61/M 1985 708 < 20 NA NA NA - NA
ES24 61/M 2009 1368 <20 NA NA NA - NA
ES34 54/M 2001 425 < 75 NA NA NA - NA
CP9 48/M 1988 1310 < 20 No 155 111,089 + 8
CP10 48/M 2007 408 < 20 No 18 297,092 + 6
CP11 47/M 1998 595 <20 No 12 300,000 + 12
CP12 50/F 2012 1293 <20 No 297 9738 + 1
CP13 50/M 2012 659 < 20 No 494 30,094 + 0.5
CP14 74/M 2004 324 <20 6800 (1) 214 60,649 + 6
CP15 44/M 2001 414 95 1281 (2) 8 155,000 + 9
CP7 61/M 2001 127 227,548 NA NA NA - NA
NA: not applicable.
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total of TW10, KF11, and IW9 peptide (3 ug/mL each), or
corresponding peptides containing escape mutations, for
7 days, with IL-2 supplemented every 48 h.
CD8+ And CD4+ T cell isolation
PBMCs were isolated by Ficoll gradient centrifugation.
CD8+ T cells were isolated from PBMC using the Miltenyi
Human CD8 Microbeads according to the manufacturer’s
instructions. CD4+ T cells were isolated from either bulk
PBMCs or CD8-depleted PBMCs using the Miltenyi
Human CD4+ T Cell Isolation Kit II according to the
manufacturer’s instructions. Purity of both cell types was
routinely greater than 95% as determined by staining with
CD3-Pacific Blue and CD8 APC or CD4 PerCP-Cy5.5 (BD).
Suppression
Freshly isolated CD4+ T cells were spinoculated as de-
scribed [76] at 1,200 × g for 2 h with one of seven NL4-3
pseudotyped viruses in 2.9 × 106 cells/tube. We typically
used 50 to 100 ng p24 virus for 100,000 CD4+ T cells which
typically resulted in 2 to 10% GFP positive cells. Cells
without virus were spinoculated as a negative control.
After spinoclulation, CD4+ T cells were washed and plated
in a 96 well plate at 0.1 × 105 cells / well in RPMI 1640
supplemented with 10% FBS. Unstimulated, wild type
stimulated, or Mutant stimulated CD8+ T cells were
immediately added to the spinoculated CD4+ T cells, at
specified ratios. Cells were cultured for 3 or 5 days before
fixation and staining (CD3 Pacific Blue, CD8 APC, BD)
and analysis by flow cytometry on a FACSCanto II (BD).Intracellular cytokine analysis
0.5 × 106 unstimulated or stimulated PBMCs (from above)
were restimulated with peptide (2 ug/mL), anti-CD28, and
anti-CD49d in the presence of GolgiStop and GolgiPlug
(BD) for 12 h. After staining with CD3 PE and CD8
APC-H7 (BD), cells were fixed and permeablized with
Cytoperm/Cytofix Kit (BD). Cytokines were stained
using IFN-γ PerCP-Cy5.5 (BD) and Perforin FITC (Cell
Sciences). Stained cells were analyzed by flow cytometry
on a FACSCanto II (BD).
Viral quantification
Concentrated virus was quantified by q-RTPCR. Viral
RNA was isolated in triplicate with ZR Viral RNA Kit
(Zymogen), and RT was performed using Superscript III
First-Strand Synthesis Kit (Invitrogen) using poly(dT)20
primers. VQA qPCR was performed as described [77].
In brief, Taqman Fast Advanced Master Mix (Invitrogen)
was used with primers 5′ cagatgctgcatataagcagctg and 5′
ttttttttttttttttttttttttgaagcac, and run on a ViiA7 (AB).
Fitness assay
PBMCs were isolated from healthy donors by Ficoll
gradient centrifugation and activated in RPMI 1640
supplemented with IL-2 (100 units/mL) and PHA
(1 ug/mL) for 3 days. CD4+ T cells were isolated (as above)
and spinoculated (1,200 × g, 2 h) in a 96-well plate with
0.1 × 106 cells / well, with different concentrations of each
virus as shown in Figure 1. 72 h after spinoculation, cells
were fixed (3.3% formaldehyde) and the level of infection
for each concentration of virus was analyzed by flow
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used to generate model curves. Relative fitness was
determined as a percentage of the maximal infection of
an individual virus relative to the wild type control.
Additional files
Additional file 1: Figure S1. Theoretical nonlinear regression curves
plotted with each escape variant. Data generated in fitness assay is
shown here (wild type, black; I147L, orange; A146P, navy; A163S, red;
A146P/A163S, purple; T242N/G248A, brown; A146P/A163S/T242N/G248A,
teal). Black line depicts theoretical nonlinear regression curve generated
by GraphPad. R2 values for each theoretical curve is show on the bottom
right of individual plots. Plot on the bottom right depicts all theoretical
curves corresponding to NL4-3 variant color on the same plot.
Additional file 2: Figure S2. Comparison of stimulation status for
suppressive function. Suppressive capacity of CD8+ T cells, either
unstimulated or stimulated with peptides corresponding to HLA-B*57
Gag epitope (WT) or escape mutant variant (Mutant), is compared for
each of seven different escape mutant variant viruses used (wild type,
black; I147L, orange; A146P, navy; A163S, red; A146P/A163S, purple;
T242N/G248A, brown; A146P/A163S/T242N/G248A, teal). Suppression on
day 3 (left) and day 5 (right) is shown. n=7.
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